These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33843947)

  • 1. Buprenorphine Opioid Treatment During the COVID-19 Pandemic-Reply.
    Nguyen TD; Saloner B; Stein BD
    JAMA Intern Med; 2021 Aug; 181(8):1135-1136. PubMed ID: 33843947
    [No Abstract]   [Full Text] [Related]  

  • 2. Buprenorphine Opioid Treatment During the COVID-19 Pandemic.
    Luigi M; Luo M; Maes EJP
    JAMA Intern Med; 2021 Aug; 181(8):1135. PubMed ID: 33843962
    [No Abstract]   [Full Text] [Related]  

  • 3. TIME TO REVISIT UNEVEN POLICY IN THE UNITED STATES FOR MEDICATION FOR OPIOID USE DISORDER DURING COVID-19.
    Pena E; Ahmed S
    Addiction; 2020 Oct; 115(10):1978-1979. PubMed ID: 32447795
    [No Abstract]   [Full Text] [Related]  

  • 4. Buprenorphine Dispensing in Pennsylvania During the COVID-19 Pandemic, January to October 2020.
    Chalasani R; Shinabery JM; Goetz CT; Chang CH; Yang Q; Suda KJ; Gellad WF
    J Gen Intern Med; 2021 Dec; 36(12):3915-3917. PubMed ID: 34378112
    [No Abstract]   [Full Text] [Related]  

  • 5. Rapid upscale of depot buprenorphine (CAM2038) in custodial settings during the early COVID-19 pandemic in New South Wales, Australia.
    Roberts J; White B; Attalla D; Ward S; Dunlop AJ
    Addiction; 2021 Feb; 116(2):426-427. PubMed ID: 32888226
    [No Abstract]   [Full Text] [Related]  

  • 6. Prescribing of Opioid Analgesics and Buprenorphine for Opioid Use Disorder During the COVID-19 Pandemic.
    Currie JM; Schnell MK; Schwandt H; Zhang J
    JAMA Netw Open; 2021 Apr; 4(4):e216147. PubMed ID: 33856474
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leveraging pharmacists to maintain and extend buprenorphine supply for opioid use disorder amid COVID-19 pandemic.
    Peckham AM; Ball J; Colvard MD; Dadiomov D; Hill LG; Nichols SD; Tallian K; Ventricelli DJ; Tran TH
    Am J Health Syst Pharm; 2021 Mar; 78(7):613-618. PubMed ID: 33411894
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Threshold Telemedicine-based Opioid Treatment for Criminal Justice Involved Adults During the COVID-19 Pandemic: A Case Report.
    Flavin L; Tofighi B; Krawczyk N; Schatz D; McNeely J; Butner J
    J Addict Med; 2022 Jan-Feb 01; 16(1):e59-e61. PubMed ID: 35120069
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Community Partnership to Improve Access to Buprenorphine in a Homeless Population.
    Leo P; Gastala N; Fleurimont J; Messmer S; Maes P; Richardson J; Neeb C; Stackhouse N; Koruba S; Watson DP
    Ann Fam Med; 2021; 19(1):85. PubMed ID: 33431401
    [No Abstract]   [Full Text] [Related]  

  • 10. The intertwined expansion of telehealth and buprenorphine access from a prescriber hub.
    Moore DT; Wischik DL; Lazar CM; Vassallo GG; Rosen MI
    Prev Med; 2021 Nov; 152(Pt 2):106603. PubMed ID: 33974959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changes in the availability of medications for opioid use disorder in prisons and jails in the United States during the COVID-19 pandemic.
    Dadiomov D; Trotzky-Sirr R; Shooshtari A; Qato DM
    Drug Alcohol Depend; 2022 Mar; 232():109291. PubMed ID: 35033953
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lessons from COVID 19: Are we finally ready to make opioid treatment accessible?
    Krawczyk N; Fingerhood MI; Agus D
    J Subst Abuse Treat; 2020 Oct; 117():108074. PubMed ID: 32680610
    [No Abstract]   [Full Text] [Related]  

  • 13. Medication treatment for opioid use disorder and community pharmacy: Expanding care during a national epidemic and global pandemic.
    Cochran G; Bruneau J; Cox N; Gordon AJ
    Subst Abus; 2020; 41(3):269-274. PubMed ID: 32697171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mobile Telemedicine for Buprenorphine Treatment in Rural Populations With Opioid Use Disorder.
    Weintraub E; Seneviratne C; Anane J; Coble K; Magidson J; Kattakuzhy S; Greenblatt A; Welsh C; Pappas A; Ross TL; Belcher AM
    JAMA Netw Open; 2021 Aug; 4(8):e2118487. PubMed ID: 34448869
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Buprenorphine maintenance treatment in patients with opioid use disorder diagnosed with COVID-19.
    Frost M
    J Opioid Manag; 2020; 16(6):405-407. PubMed ID: 33428187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use and misuse of opioid agonists in opioid addiction.
    Modesto-Lowe V; Swiezbin K; Chaplin M; Hoefer G
    Cleve Clin J Med; 2017 May; 84(5):377-384. PubMed ID: 28530896
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Removing One Barrier to Opioid Use Disorder Treatment: Is It Enough?
    Weimer MB; Wakeman SE; Saitz R
    JAMA; 2021 Mar; 325(12):1147-1148. PubMed ID: 33630020
    [No Abstract]   [Full Text] [Related]  

  • 18. The COVID-19 pandemic and opioid use disorder: Expanding treatment with buprenorphine, and combining safety precautions with telehealth.
    Cales RH; Cales SC; Shreffler J; Huecker MR
    J Subst Abuse Treat; 2022 Feb; 133():108543. PubMed ID: 34210567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. "How will I get my next week's script?" Reactions of Reddit opioid forum users to changes in treatment access in the early months of the coronavirus pandemic.
    Krawczyk N; Bunting AM; Frank D; Arshonsky J; Gu Y; Friedman SR; Bragg MA
    Int J Drug Policy; 2021 Jun; 92():103140. PubMed ID: 33558165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Controlling the Swing of the Opioid Pendulum.
    Comerci G; Katzman J; Duhigg D
    N Engl J Med; 2018 Feb; 378(8):691-693. PubMed ID: 29466151
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.